Compare YSXT & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | ACET |
|---|---|---|
| Founded | 2011 | 1947 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 69.6M |
| IPO Year | N/A | 2017 |
| Metric | YSXT | ACET |
|---|---|---|
| Price | $1.30 | $7.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $56.00 |
| AVG Volume (30 Days) | ★ 335.5K | 117.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.45 |
| 52 Week High | $9.90 | $9.05 |
| Indicator | YSXT | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 50.17 |
| Support Level | $1.08 | $6.54 |
| Resistance Level | $1.47 | $8.46 |
| Average True Range (ATR) | 0.15 | 0.46 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 41.30 | 37.24 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.